Search Bar & Filters
Found 942 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome who are treated with osilodrostat combined with glucocorticoid replacement therapy. The study also aims to assess new steroid biomarkers for dosing adequacy, and to monitor the safety, durability, and clinical improvement during treatment. The treatment starts with a Phase 1 titration period where participants take osilodrostat with added methylprednisolone as replacement therapy. Osilodrostat dosage is gradually increased to reach targeted cortisol levels, while participants are closely monitored. After reaching maintenance doses, participants enter Phase 2, a maintenance phase lasting 48 weeks, during which cortisol levels and other clinical measures are periodically assessed. Participants provide informed consent and receive frequent assessments including blood and urine tests for cortisol and steroid profiles. Communication with study staff is frequent in the early treatment phase to monitor for adrenal insufficiency signs. Outcome measures include adrenal insufficiency events, cortisol levels, symptom frequency, blood pressure, weight changes, medication use, and quality of life scores. The study lasts approximately 48 weeks from the first osilodrostat dose.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.
Actively Recruiting
Researchers are studying ways to prevent cytomegalovirus CMV infection in children and adolescents who have received a kidney transplant and weigh less than 40 kilograms. This trial focuses on understanding how the drug letermovir behaves in the body over time and assessing its safety and tolerance in this young population. The study is a phase 1, open-label, single-arm trial sponsored by Merck Sharp & Dohme LLC. Participants who are between 4 and 52 weeks post-kidney transplant will receive oral letermovir, either as tablets or pellets, or via gastrostomy or nasogastric tube pellets only for 7 consecutive days. The study uses weight-banded dosing to tailor the treatment to each child or adolescents weight. During the study, participants will be closely monitored with blood sampling to measure letermovir levels over a 24-hour period on Day 7. Researchers will also track any adverse events for up to 21 days and note if any participant stops the treatment due to side effects within 7 days. The total study duration for each participant includes the treatment period and safety monitoring, extending until the primary outcome data is collected.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.
Actively Recruiting
Researchers are evaluating the safety and effects of ETX101, a gene therapy, in children with SCN1A-positive Dravet syndrome. This study includes infants and children from 6 months to under 18 years, with different age groups in each part. It is a Phase 12 multicenter study with open-label and randomized, double-blind, sham delayed-treatment control designs to assess ETX101s impact. The study has three parts Part 1A tests increasing doses of ETX101 in young children aged 6 to under 36 months Part 1B tests one dose level in children aged 48 months to under 18 years Part 2 compares a single dose of ETX101 to a sham procedure in children aged 6 to under 48 months. Part 2 participants are randomly assigned to treatment or sham groups in a 21 ratio, with masking through 52 weeks. Participants will be involved in treatment and observation over up to 52 weeks post-dosing, with monitoring of monthly seizure frequency and developmental assessments using Bayley-4 and Vineland-3 scales. Researchers will measure changes in seizures and cognitive and adaptive behaviors. Safety and efficacy are tracked through clinical evaluations, and the primary outcome focuses on seizure frequency changes from before treatment to weeks 5 through 52.
Actively Recruiting
This research aims to evaluate a new program called Strengthening COnnections to Overcome Pain SCOOP designed for older adults living in rural areas who experience chronic pain and loneliness. The study seeks to find out if participating in SCOOP reduces how much pain interferes with daily life and decreases feelings of loneliness, while also measuring participant engagement in the program. The SCOOP program lasts 7 weeks and is delivered mainly over the telephone by community health workers. Participants in the SCOOP group will watch brief weekly videos teaching strategies for managing pain and improving social connections, followed by coaching sessions with a community health worker to support behavioral goal-setting and connect participants to helpful resources. A control group will receive usual care and later be offered educational materials and a workshop. Participants will complete two telephone interviews one at the start of the study and another 8 weeks later to assess changes in pain interference, loneliness, and satisfaction with the program. Researchers will track how many coaching sessions are completed as a measure of engagement. The total participation spans the 7-week intervention period plus follow-up assessments, with the study concluding in May 2027.
1-10 of 942
1